12 Month Price Forecast For ACAD
Distance to ACAD Price Forecasts
ACAD Price Momentum
๐ค Considering ACADIA Pharmaceuticals (ACAD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 10:28 PM UTC
ACAD Analyst Ratings & Price Targets
Based on our analysis of 31 Wall Street analysts, ACAD has a consensus that is bullish. The median price target is $26.00, with forecasts ranging from $11.00 to $39.00. Currently, there are 13 Buy ratings, 6 Hold ratings, and 1 Sell ratings.
With ACAD currently trading at $17.26, the median price forecast suggests a 50.6% upside. The most optimistic forecast comes from Jason Butler at JMP Securities, projecting a 126.0% upside, while at provides the most conservative target, suggesting a -36.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACAD Analyst Consensus
ACAD Price Target Range
Latest ACAD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACAD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2024 | Needham | Ami Fadia | Buy | Reiterates | $28.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $27.00 |
| Oct 10, 2024 | Raymond James | Danielle Brill | Market Perform | Reinstates | $0.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $27.00 |
| Aug 8, 2024 | UBS | Ashwani Verma | Buy | Maintains | $23.00 |
| Aug 8, 2024 | Citigroup | David Hoang | Buy | Maintains | $23.00 |
| Aug 7, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Maintains | $28.00 |
| Aug 7, 2024 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Downgrade | $20.00 |
| Aug 7, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $26.00 |
| Aug 7, 2024 | Needham | Ami Fadia | Buy | Maintains | $28.00 |
| Jul 12, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $28.00 |
| Jun 27, 2024 | BMO Capital | Keith Tapper | Outperform | Initiates | $31.00 |
| Jun 25, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $29.00 |
| May 10, 2024 | B of A Securities | Tazeen Ahmad | Neutral | Maintains | $22.00 |
| May 9, 2024 | Mizuho | Uy Ear | Neutral | Maintains | $21.00 |
| May 9, 2024 | Baird | Joel Beatty | Outperform | Maintains | $28.00 |
| May 9, 2024 | Stifel | Paul Matteis | Hold | Maintains | $21.00 |
| May 9, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $27.00 |
| May 9, 2024 | Needham | Ami Fadia | Buy | Reiterates | $30.00 |
| May 9, 2024 | Citigroup | David Hoang | Buy | Maintains | $30.00 |
ACADIA Pharmaceuticals Inc (ACAD) Financial Data
ACADIA Pharmaceuticals Inc has a market capitalization of $3.00B with a P/E ratio of 22.1x. The company generates $929.24M in trailing twelve-month revenue with a 13.8% profit margin.
Revenue growth is +18.3% quarter-over-quarter, while maintaining an operating margin of +12.6% and return on equity of +27.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
ACADIA Pharmaceuticals Inc (ACAD) Company Overview
About ACADIA Pharmaceuticals Inc
Develops treatments for CNS disorders and rare diseases.
The company generates revenue by developing and commercializing innovative biopharmaceuticals, focusing on therapies for central nervous system disorders and rare diseases. It markets NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett Syndrome, while also advancing several compounds through various stages of clinical trials aimed at addressing significant unmet medical needs.
ACADIA has strategic partnerships with Neuren Pharmaceuticals and Stoke Therapeutics to enhance its development capabilities in novel treatments. The company, formerly known as Receptor Technologies, Inc., has a strong pipeline with multiple candidates in different phases of clinical trials, indicating a robust commitment to research and development in CNS-related therapeutics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
620
CEO
Ms. Catherine E. Owen Adams
Country
United States
IPO Year
2004
Website
www.acadia.comACADIA Pharmaceuticals Inc (ACAD) Latest News & Analysis
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
2 days agoAcadia Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million. They will pay Neuren Pharmaceuticals one-third of the net proceeds.
Acadia Pharmaceuticals' $150 million PRV sale boosts liquidity, signaling potential for growth and strategic reinvestment, impacting investor confidence and stock performance.
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
4 days agoAcadia Pharmaceuticals appointed Thomas Andrew Garner as Chief Commercial Officer to lead commercial strategy and operations, aiming for growth and product expansion in U.S. and international markets.
The appointment of Thomas Andrew Garner as Chief Commercial Officer signals a focus on growth and expansion for Acadia Pharmaceuticals, potentially impacting stock performance and investor confidence.
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
10 days agoZacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Zacks Style Scores enhance stock selection across investment strategies, potentially leading to better returns and informed decisions for investors seeking strong stock opportunities.
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
16 days agoAcadia has secured a $610 million exclusive global license from Saniona to develop and commercialize SAN711 for neurological disorders.
The $610 million licensing deal signals Acadia's commitment to expanding its neurological portfolio, potentially leading to growth in revenue and market value, influencing investor sentiment positively.
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
17 days agoAcadia Pharmaceuticals has secured a worldwide license from Saniona for SAN711, a GABAA-ฮฑ3 modulator, targeting essential tremor for development and commercialization.
Acadia's licensing deal for SAN711 could enhance its product pipeline, potentially leading to new revenue streams and increased market competitiveness in neurology, affecting stock performance.
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
16 days agoNUPLAZID and DAYBUE are experiencing double-digit sales growth. The company aims for over $1 billion in annual sales by 2025, with potential growth from ACP-101 and ACP-204.
Double-digit sales growth for NUPLAZID and DAYBUE signals strong market demand, while projected $1 billion sales by 2025 and upcoming late-stage assets indicate significant future revenue potential.
Frequently Asked Questions About ACAD Stock
What is ACADIA Pharmaceuticals Inc's (ACAD) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, ACADIA Pharmaceuticals Inc (ACAD) has a median price target of $26.00. The highest price target is $39.00 and the lowest is $11.00.
Is ACAD stock a good investment in 2025?
According to current analyst ratings, ACAD has 13 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $17.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ACAD stock?
Wall Street analysts predict ACAD stock could reach $26.00 in the next 12 months. This represents a 50.6% increase from the current price of $17.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ACADIA Pharmaceuticals Inc's business model?
The company generates revenue by developing and commercializing innovative biopharmaceuticals, focusing on therapies for central nervous system disorders and rare diseases. It markets NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett Syndrome, while also advancing several compounds through various stages of clinical trials aimed at addressing significant unmet medical needs.
What is the highest forecasted price for ACAD ACADIA Pharmaceuticals Inc?
The highest price target for ACAD is $39.00 from Jason Butler at JMP Securities, which represents a 126.0% increase from the current price of $17.26.
What is the lowest forecasted price for ACAD ACADIA Pharmaceuticals Inc?
The lowest price target for ACAD is $11.00 from at , which represents a -36.3% decrease from the current price of $17.26.
What is the overall ACAD consensus from analysts for ACADIA Pharmaceuticals Inc?
The overall analyst consensus for ACAD is bullish. Out of 31 Wall Street analysts, 13 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $26.00.
How accurate are ACAD stock price projections?
Stock price projections, including those for ACADIA Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
